Home Newsfeeds Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.62) by 33.87 percent.

Walmart, PriceSmart And 2 Other Stocks Insiders Are Selling

By Avi Kapoor

April 30, 8:25 AM

The Nasdaq 100 closed higher by 0.4% on Monday. Investors, meanwhile, focused on some notable insider trades. When…

IMAX

What’s Going On With Elevation Oncology Stock?

By Erica Kollmann

January 8, 5:16 PM

Elevation Oncology, Inc. (NASDAQ: ELEV) shares raced higher Monday. The company announced program updates and upcoming 2024 milestones on Friday.

ELEV

T2 Biosystems Announces FDA 510(k) Submission To Expand Use Of The FDA-Cleared T2Candida Panel To Include Pediatric Testing

By Benzinga Newsdesk

January 3, 10:01 AM

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food

TTOO

THC Infused Lemonade, ‘Vicious Citrus’ Gains Wider Distribution In New Deal

By Vuk Zdinjak

September 13, 11:18 AM

Xebra Brands Ltd. (OTCQB: XBRAF) (CSE:XBRA) (FSE:9YC), a cannabis company, is launching its Vicious Citrus cannabis infused lemonade in the province of Saskatchewan.

CSE:XBRA

Quoin Pharmaceuticals Q4 EPS $(0.41) Beats $(0.62) Estimate

Related Posts

Walmart, PriceSmart And 2 Other Stocks Insiders Are Selling

What’s Going On With Elevation Oncology Stock?

T2 Biosystems Announces FDA 510(k) Submission To Expand Use Of The FDA-Cleared T2Candida Panel To Include Pediatric Testing

THC Infused Lemonade, ‘Vicious Citrus’ Gains Wider Distribution In New Deal